These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 32905674)

  • 1. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
    Konkle BA; Shapiro AD; Quon DV; Staber JM; Kulkarni R; Ragni MV; Chhabra ES; Poloskey S; Rice K; Katragadda S; Fruebis J; Benson CC
    N Engl J Med; 2020 Sep; 383(11):1018-1027. PubMed ID: 32905674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
    Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
    Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
    Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
    Malec L; Peyvandi F; Chan AKC; Königs C; Zulfikar B; Yuan H; Simpson M; Álvarez Román MT; Carcao M; Staber JM; Dunn AL; Chou SC; d'Oiron R; Albisetti M; Demissie M; Santagostino E; Yarramaneni A; Wong N; Abad-Franch L; Gunawardena S; Fijnvandraat K;
    N Engl J Med; 2024 Jul; 391(3):235-246. PubMed ID: 39018533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
    N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
    Lissitchkov T; Willemze A; Katragadda S; Rice K; Poloskey S; Benson C
    Blood Adv; 2022 Feb; 6(4):1089-1094. PubMed ID: 34794179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Shah A; Solms A; Wiegmann S; Ahsman M; Berntorp E; Tiede A; Iorio A; Mancuso ME; Zhivkov T; Lissitchkov T
    Ann Hematol; 2019 Sep; 98(9):2035-2044. PubMed ID: 31236667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
    Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
    N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
    Katragadda S; Neelakantan S; Diao L; Wong N
    J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
    Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
    N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M; Aleman MM; Kistanova E; Peters R; Salas J; Seth Chhabra E
    J Thromb Haemost; 2022 Jul; 20(7):1674-1683. PubMed ID: 35466511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
    Mahlangu J; Powell JS; Ragni MV; Chowdary P; Josephson NC; Pabinger I; Hanabusa H; Gupta N; Kulkarni R; Fogarty P; Perry D; Shapiro A; Pasi KJ; Apte S; Nestorov I; Jiang H; Li S; Neelakantan S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Dodd N; Nugent K; Vigliani G; Luk A; Brennan A; Pierce GF;
    Blood; 2014 Jan; 123(3):317-25. PubMed ID: 24227821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.
    Fuller JR; Knockenhauer KE; Leksa NC; Peters RT; Batchelor JD
    Blood; 2021 May; 137(21):2970-2980. PubMed ID: 33569592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.